Skip to content

Science News About Medications

Designer Agent Blocks Pain in Mice Without Morphine’s Side Effects

Science Update

Scientists have synthesized a molecule with a unique profile of highly specific pain-relieving properties and demonstrated its efficacy in mice.

Continue Reading

Ketamine Lifts Depression via a Byproduct of its Metabolism

Press Release

A chemical byproduct, or metabolite, created as the body breaks down likely holds the secret to its rapid antidepressant action .

Continue Reading

Team-based Treatment for First Episode Psychosis Found to be High Value

Press Release

Coordinated Specialty Care for First Episode Psychosis is Cost Effective

Continue Reading

Antipsychotics Use Among Older Adults Increases with Age

Press Release

Researchers find antipsychotic use among older adults increases with age despite known health risks. In 2010, more than 3/4 of seniors receiving an antipsychotic prescription had no documented clinical psychiatric diagnosis during the year. In addition, among those who did have a diagnosed mental disorder and/or dementia, nearly half of the oldest patients had dementia, regardless of FDA warnings that antipsychotics increase mortality in people with dementia.

Continue Reading

Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age

Press Release

Boys are more likely than girls to receive an antipsychotic prescription regardless of age, according to a new study published in JAMA Psychiatry.

Continue Reading

Despite Risks, Benzodiazepine Use Highest in Older People

Press Release

Prescription use of benzodiazepines—a widely used class of sedative and anti-anxiety medications—increases steadily with age, despite the known risks for older people, according to a comprehensive analysis of benzodiazepine prescribing in the United States.

Continue Reading

Medications for Patients with First Episode Psychosis May Not Meet Guidelines

Press Release

Many patients with first-episode psychosis receive medications that do not meet guidelines. A study finds that almost 40 % of people with first-episode psychosis in community mental health clinics across the country might benefit from medication treatment changes.

Continue Reading

Rapid Agent Restores Pleasure-seeking Ahead of Other Antidepressant Action

Press Release

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of – and ahead of – its other antidepressant effects.

Continue Reading

For Schizophrenia, Newer Injectables Not Necessarily Better

Science Update

Treatment adherence is a problem among people with schizophrenia, who may not take medications because they don’t perceive its need or benefit, don’t like the side effects, or forget. To combat this issue, long-acting injectable medications are administered every 2-4 weeks. But are the new forms of these drugs better than the old ones?

Continue Reading

Webinar on Ketamine and Next Generation Therapies Featuring NIMH’s Carlos A. Zarate, M.D.

Science Update

On August 13, 2013, Carlos A. Zarate, M.D., from the National Institute of Mental Health will give a live presentation titled “Ketamine & Next Generation Therapies,” where he will discuss his research on novel medications for treatment-resistant depression and bipolar disorder at the Brain and Behavior Research Foundation.

Continue Reading

NIH Funds Industry Collaborations to Identify New Uses for Existing Compounds

Press Release

NIH Funds Industry Collaborations to Identify New Uses for Existing Compounds

Continue Reading

Ketamine Cousin Rapidly Lifts Depression Without Side Effects

Science Update

NMDA or glutamate receptor modulators as antidepressants have come of age. Human clinical studies demonstrated that ketamine can ward off depressive symptoms within 2 hours of administration and last for several days. Yet serious side effects are attached to this drug, including excessive sleepiness, hallucinations, and substance abuse behavior.

Continue Reading

Long-term Course of ADHD Diagnosed in Preschool Years Can be Chronic and Severe

Science Update

Long-term Course of ADHD Diagnosed in Preschool Years Can be Chronic and Severe

Continue Reading